Ablynx : PUBLICATION IN ACCORDANCE WITH ARTICLES 14 AND 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR

Ablynx : PUBLICATION IN ACCORDANCE WITH ARTICLES 14 AND 15 OF THE BELGIAN LAW
  OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY
                                    LAW")

REGULATED INFORMATION

GHENT,  Belgium,  8  March  2013  -  Ablynx  [Euronext  Brussels:  ABLX],  the 
biopharmaceutical  company  focused  on  the  discovery  and  development   of 
Nanobodies®, announces  today  that  the  closing  of  its  private  placement 
("Accelerated Bookbuild Offering"/"ABO") took place on  5 March 2013 and as  a 
result, Ablynx issued 4,377,919  new shares. In  addition, 348,400 new  shares 
were issued that same day as a result of the exercise of 641,800 warrants.

Ablynx NV also publishes the following information in accordance with  article 
15 of the  Law of  2 May  2007 on the  publication of  major shareholdings  in 
issuers whose  shares are  admitted  to trading  on  a regulated  market  (the 
"Transparency Law"):

Total amount of the share capital:                 €90,653,858.30
Total number of securities carrying voting rights: 48,505,516
Total number of voting rights (denominator):       48,505,516

Ablynx NV  has in  total 3,904,145  outstanding warrants,  of which  1,657,700 
warrants give the holder the right to a total of 828,850 shares (two  warrants 
giving the right to  subscribe to one share)  and of which 2,246,445  warrants 
give the holder the right to a  total of 2,246,445 shares (one warrant  giving 
the right to subscribe  to one share). The  acceptance and issuing of  467,500 
warrants (one warrant giving the right to subscribe to one share) is  pending. 
The total number of voting  rights, which can be acquired  as a result of  the 
exercise of the outstanding warrants, amounts to 3,075,295.

In addition, Ablynx NV announces, in accordance with article 14 of the Law  of 
2 May 2007 on the publication  of major shareholdings in issuers whose  shares 
are admitted to trading on a  regulated market (the "Transparency Law"),  that 
it has received the following  transparency notifications between 28  February 
and 7 March 2013.

Notifier(s)                              Number of voting Percentage of voting
                                         rights           rights
Gimv NV, Adviesbeheer Gimv Life Sciences    5,825,939            12.01%
NV, Adviesbeheer Gimv Life Sciences 2004
NV and Biotech Fonds Vlaanderen NV^1
Sofinnova Partners SAS                      4,675,587            9.63%

^1 Gimv NV controls Adviesbeheer Gimv  Life Sciences NV and Adviesbeheer  Gimv 
Life Sciences 2004 NV.  Gimv NV (2,463,320  voting rights), Adviesbeheer  Gimv 
Life Sciences NV (0  voting rights), Adviesbeheer Gimv  Life Sciences 2004  NV 
(433,745 voting  rights) and  Biotech Fonds  Vlaanderen NV  (2,928,874  voting 
rights) are acting in mutual agreement.  The Flemish Region in Belgium is  the 
ultimate shareholder of Biotech Fonds Vlaanderen NV.

The full  versions of  the  transparency notifications  are available  on  the 
website of Ablynx (www.ablynx.com - investor relations).

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies^®, a novel class of therapeutic proteins based on  single-domain 
antibody  fragments,  for  a  range  of  serious  human  diseases,   including 
inflammation, haematology, oncology and pulmonary disease. Today, the  Company 
has approximately  25  programmes  in  the pipeline  and  five  Nanobodies  at 
clinical development stage.  Ablynx has on-going  research collaborations  and 
significant  partnerships  with   major  pharmaceutical  companies   including 
Boehringer Ingelheim, Merck Serono,  Novartis and Merck &  Co. The Company  is 
headquartered in Ghent, Belgium.

More information can be found on www.ablynx.com.

For more information, please contact

Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
 +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
e: ablynx@mcomgroup.com

press release in pdf

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Ablynx via Thomson Reuters ONE
HUG#1684075
 
Press spacebar to pause and continue. Press esc to stop.